الفهرس 
The prognostic and diagnostic value>of serum endocan in Egyptian acute myeloid leukemia patients
List of contentsOnly 14 pages are availabe for public view
 |  | from | 263 |  |  |
| | | from | 263 | | |
Abstract
Acute leukemia is a common bone marrow malignancy with poor prognosis, the leukemia-induced increase in bone marrow microvascularity is important both for leukemogenesis and chemosensitivity in acute myeloid leukemia, so identification of biomarkers for leukemia associated angiogenesis, would be important for diagnosis and prognosis ofthe disease. An important fact that leukemic pathogenesis involves not only clonal proliferation of stem cells but also interaction of BM angiogenesis, Endocan is a novel Proteoglycan secreted by vascular endothelium ,detected in serum, Its expression is increased in several human malignancies including acute leukemia and high expression has an adverse prognostic impact.
Our study aiming to assess the pre and post induction treatment level of serum endocan in cases of newly diagnosed acute myeloid leukemia and evaluate its validity as biomarker for diagnosis and prediction of response to treatment. included sixty subjects ,forty Acute myeloid leukemia patients, twenty age and sex matched healthy controls, adult Egyptian above 18 years from both sexes, Serum endocan level was measured using ELISA technique, Patients recieved induction chemotherapy regimen and were prospectively followed up for the response. Response to induction therapy was assessed by bone marrow examination at day 28,our results showed that there was high serum level of endocan in patients with acute myeloid leukemia, and its level decreased when the leukemia cell burden is reduced by induction chemotherapy when patients developed severe neutropenia, there was significant difference between cases passed to remission with cases showed failure of complete remission regarding pre and post treatment level of endocan ,cases passed to remission showed the lower level. So therapeutic targeting of endocan is now possible, and the possible role of endocan in acute leukemia should be further investigated.